Subscribe for email alerts

Don’t miss a single Science & Enterprise post. Sign up for our daily email alerts.

Donate to Science & Enterprise

Please share Science & Enterprise

Gut-Brain Meds Developer Going Public in Merger

Milk splashing

(Myriams-Fotos, Pixabay. https://pixabay.com/photos/milk-splash-drops-food-liquid-4755234/)

31 Oct. 2022. A developer of synthetic biology treatments for inflammatory and neurological disorders linked to the gut is becoming a public company through a special acquisition merger. Intrinsic Medicine Inc. in Seattle is joining with Phoenix Biotech Acquisition Corp. in Oakland, California, a special purpose acquisition company or SPAC, . . . → Read More: Gut-Brain Meds Developer Going Public in Merger

Dual-Action Vaccine Shown to Attack, Shrink Solid Tumors

Breast tumor microenvironment

Research with lab animals shows an experimental cancer vaccine generates immune-system cells that infiltrate solid tumors and reduce the tumor’s protective environment. . . . → Read More: Dual-Action Vaccine Shown to Attack, Shrink Solid Tumors

Trial Shows Antibody Neutralizes, Reduces HIV Virus

T-cell infected by HIV

Results from a clinical trial show an experimental one-time antibody therapy, even at low doses, lowers levels of HIV virus in people living with the disease. . . . → Read More: Trial Shows Antibody Neutralizes, Reduces HIV Virus

Immunotherapy Start-Up Launches Collaboration, Raises $65M

T-cells and cancer cells

A new biotechnology company is creating cancer immunotherapies that it says harness more of the full power of T-cells in the immune system to attack tumors. . . . → Read More: Immunotherapy Start-Up Launches Collaboration, Raises $65M

Grant Funds Regenerative Gel for Treating Skin Ulcers

Antoni Ribas

A California state research agency is funding preclinical development of a gel designed to regenerate stem cells in the skin to help heal venous skin ulcers. . . . → Read More: Grant Funds Regenerative Gel for Treating Skin Ulcers

Trial in Progress of Antibody Blocking Covid-19 in Immunocompromised

Global Covid-19

A clinical trial is underway testing a synthetic antibody designed to prevent SARS-CoV-2 viral infections in people with compromised immune systems. . . . → Read More: Trial in Progress of Antibody Blocking Covid-19 in Immunocompromised

“Dark Genome” Drug Discoverer Gains $37M in Early Funds

T lymphocyte

Colorized scanning electron micrograph of a T lymphocyte. (NIAID)

19 Oct. 2022. A biotechnology enterprise discovering new drugs from non-protein coding regions of the genome is raising €37.5 million ($US 36.6 million) in venture funds. Nucleome Therapeutics Ltd. in Oxford, U.K. is a three year-old business spun-off from genetic research labs at University . . . → Read More: “Dark Genome” Drug Discoverer Gains $37M in Early Funds

Infographic – US Biotech Venture Funds Fall in Q3

Chart: Biotech/pharma venture funds

Venture funds for U.S. biotechnology and pharmaceutical start-ups declined in the third quarter of 2022 from the 2021 record pace, but remain on track for historic highs. . . . → Read More: Infographic – US Biotech Venture Funds Fall in Q3

Trial Begins Testing RNA Hepatitis-B Treatment

Hepatitis-B virus

A clinical trial is underway testing the safety and chemical activity of a hepatitis-B therapy using engineered RNA to block production of a key protein linked to the disease. . . . → Read More: Trial Begins Testing RNA Hepatitis-B Treatment

Start-Up to Manufacture, Supply Practical Radiation Drugs

Radiation

A new company formed by a technology venture investor and the Mayo Clinic aims to produce and supply more readily available radiation drug therapies. . . . → Read More: Start-Up to Manufacture, Supply Practical Radiation Drugs